Agios Pharmaceuticals
AGIO
225 hedge funds and large institutions have $1.97B invested in Agios Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 85 increasing their positions, 71 reducing their positions, and 24 closing their positions.
71% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 24
20% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 71
8% more funds holding
Funds holding: 208 → 225 (+17)
2.79% more ownership
Funds ownership: 102.15% → 104.94% (+2.8%)
22% less call options, than puts
Call options by funds: $9.02M | Put options by funds: $11.5M
24% less capital invested
Capital invested by funds: $2.58B → $1.97B (-$616M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JFG
Jefferies Financial Group
New York
|
+$70.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$66.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$14.2M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$13M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$12.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$33.8M |
| 2 |
JP Morgan Chase
New York
|
-$32.8M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$29.7M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$19.2M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$17.6M |
AGIO Hedge Fund Activity: Q4 2024 in Review
225 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q4 2024, worth a combined $1.97B — down 24% from $2.58B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new AGIO positions and 24 closed out — a net gain of 17 holders — while 85 added to existing stakes and 71 trimmed.
The largest buyer was Jefferies Financial Group, opening a new position worth an estimated $70.5M. The largest seller was Vestal Point Capital, exiting entirely with an estimated $33.8M sold.
- 225 institutional investors held Agios Pharmaceuticals (AGIO) as of Q4 2024, up from 208 in Q3 2024.
- Funds reported $1.97B of Agios Pharmaceuticals stock for Q4 2024, down 24% quarter-over-quarter.
- 41 funds opened new Agios Pharmaceuticals positions in Q4 2024 and 24 closed out, a net change of +17 holders.
- The largest Agios Pharmaceuticals buyer in Q4 2024 was Jefferies Financial Group, an estimated $70.5M added.
- The largest Agios Pharmaceuticals seller in Q4 2024 was Vestal Point Capital, an estimated $33.8M sold.
Based on aggregated 13F filings for Q4 2024.